bluebird bio (NASDAQ:BLUE – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Earnings & Valuation
This table compares bluebird bio and TScan Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bluebird bio | $53.12 million | 1.65 | -$211.91 million | ($37.40) | -0.24 |
| TScan Therapeutics | $9.36 million | 17.16 | -$89.22 million | ($1.06) | -2.84 |
TScan Therapeutics has lower revenue, but higher earnings than bluebird bio. TScan Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| bluebird bio | -565.74% | -322.46% | -53.17% |
| TScan Therapeutics | -1,188.88% | -58.72% | -36.02% |
Insider and Institutional Ownership
87.4% of bluebird bio shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 1.4% of bluebird bio shares are held by company insiders. Comparatively, 2.8% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
bluebird bio has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for bluebird bio and TScan Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bluebird bio | 2 | 6 | 2 | 0 | 2.00 |
| TScan Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
bluebird bio currently has a consensus price target of $49.14, suggesting a potential upside of 444.82%. TScan Therapeutics has a consensus price target of $11.25, suggesting a potential upside of 273.75%. Given bluebird bio’s higher possible upside, equities research analysts plainly believe bluebird bio is more favorable than TScan Therapeutics.
Summary
TScan Therapeutics beats bluebird bio on 10 of the 14 factors compared between the two stocks.
About bluebird bio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
